The FDA has granted Orphan Drug status to Alexion Pharmaceuticals, Inc.’s humanized monoclonal antibody C5 Complement Inhibitor 5G1.1 for the treatment of patients with dermatomyositis. Alexion is currently enrolling patients in a Phase Ib pilot clinical trial that is designed to gather clinical data regarding the safety profile and biological and clinical effects of 5G1.1 Read more about Alexion Receives Orphan Drug Status For Dermatomyositis Treatment[…]